Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver cancer drug combo put to the test – but trial stops early

NCT ID NCT04777851

Terminated Disease control Sponsor: Translational Research in Oncology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial compared a combination of two drugs (regorafenib and pembrolizumab) with standard locoregional therapies (TACE or TARE) as a first treatment for intermediate-stage liver cancer that has spread beyond certain limits. The study aimed to enroll about 496 people but was terminated early after only 45 participants. Researchers were looking at how long patients lived without their cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
regorafenib and pembrolizumab
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with intermediate-stage liver cancer that is not suitable for surgery.
What could go wrong
The trial was terminated early and enrolled only 45 of a planned 496 participants, so results are limited. Both drug combinations carry risks of serious side effects, and it is unclear if the experimental arm is better than existing therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, HEPATOCELLULAR

Contacts and locations

Locations

  • Antwerp University Hospital

    Edegem, 2650, Belgium

  • CHU Amiens-Picardie

    Amiens, 80054, France

  • Center of Oncology Euroclinic Victoria Hospital

    Iași, 700106, Romania

  • Cha Bundang Medical Center

    Seongnam-si, South Korea

  • Chang Gung Memorial Hospital - Linkou

    Taoyuan, 333, Taiwan

  • Clinic for Digestive Surgery, University Clinical Center of Serbia

    Belgrade, Serbia

  • Gazi University MF

    Ankara, 6560, Turkey (Türkiye)

  • Gülhane Eğitim ve Araştırma Hastanesi

    Ankara, 6010, Turkey (Türkiye)

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, 50009, Spain

  • Humanity and Health Clinical Trial Center

    Hong Kong, 999077, Hong Kong

  • Hôpital Beaujon - APHP

    Clichy, 92110, France

  • Hôpital Henri Mondor

    Créteil, 94010, France

  • Inje University Haeundae Paik Hospital

    Busan, South Korea

  • Institue of Oncology Vojvodine Sremska Kamenica (Oncology Institute of Volvodina)

    Kamenitz, 21204, Serbia

  • Institutul Clinic Fundeni

    Bucharest, 22328, Romania

  • Israel-Georgian Medical Research Clinic Healthycore

    Tbilisi, 0112, Georgia

  • JSC VIANI Batumi Referral Hospital

    Batumi, 6010, Georgia

  • Koc University Hospital

    Istanbul, 34010, Turkey (Türkiye)

  • National Taiwan University Hospital

    Taipei, 10041, Taiwan

  • Ospedale Garibaldi Nesima

    Catania, 95122, Italy

  • Regional Institute of Gastroenterology and Hepatology "Dr Octavian Fodor"

    Cluj-Napoca, 400394, Romania

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • UCL SAINT LUC - UC Louvain

    Brussels, 1200, Belgium

  • UCLA Santa Monica Hematology Oncology

    Santa Monica, California, 90404, United States

  • Universitätsmedizin: Medizinische Klinik und Poliklinik I

    Mainz, D-55131, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.